Abstract
A molecular rational basis for the COX-2/COX-1 selectivity of lumiracoxib using molecular docking approach is described. The COX-2 docking analysis for lumiracoxib and the diclofenac analogue revealed a similar binding mode, in contrast with the COX-1 docking analysis which revealed a different binding orientation for both inhibitors.
Keywords: Cyclooxygenase-1, Cyclooxigenase-2, Molecular docking, NSAID's, Lumiracoxib, Diclofenac